Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Dordrecht

1 624 clinical trials in Dordrecht, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Dordrecht at a glance
1 624
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 624 trials in Dordrecht

Open in trial search

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Recruiting
Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:VXB-213
  • Sponsor:Sanofi Vaccines US Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+1

Recruiting

Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Asthma

Recruiting

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting
InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Chronic obstructive pulmonary disease

Recruiting

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting
Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Non-small cell lung cancer stage I

Recruiting

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Alopecia areata

Recruiting

A Phase 2a Study of ly4005130 in Adults with Severe Alopecia Areata

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:LY4005130
  • Sponsor:Eli Lilly & Co.

Small cell lung cancer

Recruiting

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Dordrecht

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on Acute Myeloid Leukemia (AML) and various forms of Multiple Myeloma, evaluating novel drug combinations and treatment approaches for patients ineligible for intensive chemotherapy.

  • Blood Cancer Therapies
  • Leukemia Treatment
  • Novel Drug Combinations

Studies aim to improve survival rates and treatment outcomes in previously untreated patients.

02 Cardiovascular Medicine

Research centered on atherosclerotic cardiovascular disease and deep vein thrombosis, investigating new therapeutic approaches and preventive strategies.

  • Heart Disease Management
  • Blood Clot Prevention
  • Cardiac Interventions

Clinical trials focus on improving patient outcomes through innovative treatments and prevention strategies.

03 Endocrine Disorders

Studies examining treatments for thyroid conditions and hormonal disorders, comparing conventional and innovative therapeutic approaches.

  • Thyroid Disease Management
  • Hormone Therapy
  • Quality of Life Improvement

Research aims to enhance treatment efficacy while minimizing side effects.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.